Herbalife (HLF) Q2 2025 earnings review
Turnaround Takes Hold: Revenue Inflection Guided for Q3 as New Product Cycle Begins
Herbalife delivered a solid Q2, beating adjusted EBITDA estimates and raising its full-year outlook for both revenue and profit. While reported net sales were still down 1.7% YoY, the company guided for a return to growth in Q3 (+0.5% to +4.5%), signaling that its strategic turnaround is gaining traction. The budding recovery is fueled by momentum in new distributor sign-ups and the launch of a new product cycle, including the MultiBurn weight-loss supplement and the beta release of its Pro2col digital wellness platform. Management's confidence is further underscored by positive volume growth in July, with North America turning positive for the first time since April 2021.
🐂 Bull Case
After multiple quarters of declines, management guided for a return to positive top-line growth in Q3. This forecast is supported by tangible momentum, including global volume growth in July and the first month of positive volume in the critical North America market in over four years.
The launch of the Pro2col digital platform and new products like MultiBurn and a healthy lifespan supplement mark a strategic pivot. These initiatives open up new revenue streams, including subscriptions, and aim to attract a new customer segment focused on personalized, data-driven wellness.
Adjusted EBITDA exceeded expectations, and the company raised its full-year guidance for both sales and profit. This demonstrates strong cost control and growing confidence in the business outlook.
🐻 Bear Case
Despite positive anecdotes about July, the reported Q2 results show key regions like North America (-3.8%) and China (-2.1%) are still contracting. The turnaround is not yet reflected in the quarterly financials.
The pivot to a tech-enabled wellness platform is a significant strategic shift. Monetization of the Pro2col app is unproven, and the 2025 guidance includes minimal revenue contribution from these new initiatives, highlighting the uncertainty of their financial impact.
A strong US dollar continues to mask underlying performance, negatively impacting reported sales by 170 basis points and adjusted EBITDA by approximately $16 million in Q2. Management noted a lag effect, suggesting currency will remain a headwind for the bottom line in the near term.
⚖️ Verdict: 🟢
Bullish. The evidence of a turnaround is becoming more concrete. The combination of a return to guided revenue growth, a beat-and-raise on profitability, and the launch of a clear, multi-pronged strategy for future growth (Pro2col, new products, subscriptions) outweighs the persistent weakness in reported Q2 numbers. Execution risk remains, but the positive momentum and strategic clarity signal an inflection point for the company.
Key Themes
Launch of Pro2col Digital Platform Signals Major Strategic Pivot
The centerpiece of the quarter was the beta launch of the 'Pro2col' digital health platform to over 7,000 distributors. This AI-assisted app provides personalized wellness plans, tracks nutrition, and connects distributors with customers. It represents a fundamental shift from a traditional direct seller to a 'high-tech, high-touch' wellness platform. The strategy aims to increase customer engagement, drive higher product usage and retention, and attract a new, more digitally-savvy customer base. The commercial launch is planned for Q4 2025 in the U.S.
Distributor Base Rebuilding Continues
While the number of new distributors was flat year-over-year in Q2, this was against a very difficult comparison from the prior year's launch of a major recruiting program. Encouragingly, four out of five regions saw year-over-year growth, led by a 16% increase in Latin America. After 12 consecutive quarters of decline ending in Q1 2024, the stabilization and growth in the distributor base is a critical leading indicator for future sales.
North America Recovery Remains a 'Show-Me' Story
Despite management highlighting a positive volume turn in July, the reported Q2 data for North America remains weak, with net sales declining 3.8% and volume down 6.0%. As a critical region, its lagging performance is a key concern. The turnaround relies heavily on converting the millions of transactional 'Nutrition Club' customers into committed product users, a challenge the new Pro2col platform is designed to address but whose success is not yet proven.
Product Innovation and Subscription Model Unlocks New Revenue
Herbalife launched MultiBurn, a non-pharmaceutical weight loss supplement, tapping into strong consumer demand. Management noted initial sales are exceeding expectations. Critically, the company is now offering MultiBurn and other products via an automatic monthly subscription model in the U.S. This shift towards recurring revenue is a significant and positive evolution of its business model.
Monetization and Execution Risk of New Tech Initiatives
The strategic pivot towards a digital platform, including the acquisition of assets from Pro2col, Pruvit, and Link Biosciences for $25.5 million, carries significant execution risk. Management confirmed that 2025 guidance includes very little revenue contribution from these initiatives. The path to monetizing the Pro2col app—whether through fees, increased product sales, or both—is still being defined, making the return on this investment uncertain.
Financial Discipline Strengthens Balance Sheet
The company continues to prioritize its financial health, maintaining its total leverage ratio at 3.0x as of June 30. Management reiterated its commitment to reduce principal debt by $1 billion by the end of 2028. This discipline provides a stable foundation for its strategic investments and has enabled the company to navigate the recent downturn without overextending its balance sheet.
Other KPIs
Exceeded the high end of the $160M-$170M guidance range. The adjusted EBITDA margin of 13.8% was down slightly from 14.1% last year, a decline management attributed entirely to a $16 million negative impact from foreign currency. This demonstrates strong underlying profitability and successful cost management from prior restructuring efforts.
Performance varied significantly by region on a constant currency basis, highlighting different stages of recovery. Latin America was the standout performer at +9.5%, benefiting from a localized strategy of price adjustments. EMEA (-1.0%) and Asia Pacific (-1.2%) were roughly stable, while China (-2.2%) and North America (-3.8%) continued to lag.
Guidance
Reversing. This is the most critical element of the outlook, signaling a definitive turn from multiple quarters of decline to positive growth. This inflection is a key validation of the company's turnaround strategy.
Accelerating. The guidance range was both raised and narrowed from the prior (-2.5% to +2.5%). The new midpoint of +1.0% (vs. 0.0% previously) reflects increased management confidence in the second half of the year.
Accelerating. The full-year profit outlook was raised from the prior range of $625M - $655M. This indicates that the expected revenue growth is profitable and that cost controls are holding firm.